Novo Nordisk A/S Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Novo Nordisk A/S Stock Forecast and Price Target
If the average price target of kr960.00 set by fourteen distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 7.71% from the last closing price in April, 2024. This potential increase is based on a high estimate of kr1120.00 and a low estimate of kr530.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.
7.71% Upside
Novo Nordisk A/S Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Novo Nordisk A/S's Price has decreased by 100.00%, from kr357.34 to kr0.00. Analysts predict that Novo Nordisk A/S's Fair Value will increase in the upcoming year, reaching kr869.35. This would represent an increase of 100.00%. Over the next seven years, experts predict that Novo Nordisk A/S's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.56 | Buy/Sell | $174.55 | 13.67% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$126.88 | Buy/Sell | $130.51 | 9.95% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£112.68 | Buy/Sell | £165.99 | 43.61% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF88.94 | Buy/Sell | CHF105.00 | 18.41% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF229.70 | Buy/Sell | CHF307.83 | 18.63% |
Novo Nordisk A/S Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Novo Nordisk A/S's Revenue has seen an increase, rising from kr126.95B to kr232.26B. This represents a growth of 82.96%. Analysts predict that Novo Nordisk A/S's Revenue will increase in the upcoming year, reaching kr275.75B. This would represent an increase of 18.72%. Over the next eight years, experts predict that Novo Nordisk A/S's Revenue will grow at a rate of 126.01%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.59 | Buy/Sell | $118.92 | 18.04% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.32 | Buy/Sell | $32.87 | 15.88% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$273.54 | Buy/Sell | $303.65 | 15.98% |
.jpg)
Novo Nordisk A/S Dividend per Share Forecast for 2023 - 2025 - 2030
Novo Nordisk A/S's Dividend per Share has seen growth In the last three years, going from kr9.10 to kr9.40 – a gain of 3.30% In the next year, analysts believe that Dividend per Share will reach kr10.50 – an increase of 11.70%. For the next seven years, the forecast is forDividend per Share to grow by 41.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
16
|
88.85€ | Buy/Sell | 102.80€ | 21.55% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$81.29 | Buy/Sell | $92.47 | 17.48% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.99 | Buy/Sell | $58.15 | 12.27% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$68.99 | Buy/Sell | $70.14 | 5.81% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.97 | Buy/Sell | $205.51 | -27.17% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.03 | Buy/Sell | $87.82 | 19.35% |
Novo Nordisk A/S EBITDA Forecast for 2023 - 2025 - 2030
Novo Nordisk A/S's EBITDA has grown in the last three years, jumping from kr58.58B to kr109.81B – an increase of 87.45%. In the next year, analysts predict that EBITDA will reach kr133.70B – an increase of 21.75%. For the next seven years, the forecast is for EBITDA to grow by 111.62%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.51 | Buy/Sell | £17.30 | 18.11% |
| SHW Stock Forecast | Sherwin Williams | Outperform |
15
|
$302.36 | Buy/Sell | $317.38 | 12.36% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.66k | Buy/Sell | ¥5.24k | 24.38% |
Novo Nordisk A/S EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Novo Nordisk A/S's EBIT has increased by 90.89%, going from kr54.48B to kr103.99B. In the next year, analysts are expecting an increase in EBIT, predicting it will reach kr122.82B – an increase of 18.11%. The Novo Nordisk A/S forecast is for EBIT to reach kr293.75B or grow by 182.48%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.12k | Buy/Sell | ¥4.74k | 10.38% |
| PPG Stock Forecast | PPG Industries | Outperform |
13
|
$130.43 | Buy/Sell | $159.04 | 22.06% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$193.18 | Buy/Sell | $299.62 | 51.15% |
Novo Nordisk A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Novo Nordisk A/S's EPS has decreased by 100.00%, from kr9.01 to kr0.00. Analysts predict that Novo Nordisk A/S's EPS will increase in the upcoming year, reaching kr21.92. This would represent an increase of 100.00%. Over the next seven years, experts predict that Novo Nordisk A/S's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
27.35€ | Buy/Sell | 45.15€ | 17.00% |
| HZNP Stock Forecast | Horizon Therapeutics Public | - |
16
|
$115.69 | Buy/Sell | $116.50 | -100.00% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$146.07 | Buy/Sell | $245.24 | 47.19% |
.jpg)